It has been hypothesized that the mechanisms behind the association between blood group A and gastric carcinoma is that the carcinoma cells produce an antigen immunologically related to blood group A, which particularly in O-individuals may have a protective effect by preventing the growth and spread of the tumour. The hypothesis predicts that O-individuals would have a longer survival time than A-individuals and that eventually the protective effect in blood group·would be somewhat stronger in women with multiple pregnancies. The results showed a significantly lower frequency of blood group·in females and a tendency towards a longer survival time in O-individuals among gastric cancer patients, but the relationship between blood group·and number of children was not in the expected direction. Thus the observations gave only partial support for the hypothesis that the associaton betwen ABO blood groups and gastric carcinoma is dependent on the antigenicity of the neoplasm. The data showed a significantly higher prevalence of gastric carcinoma and a lower average survival time in male patients.

Keywords:
Gastric carcinoma, ABO blood groups, Antigenicity of neoplasms
This content is only available via PDF.
© 1987 S. Karger AG, Basel
1987
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.